Ridogrel (BioDeep_00000033307)

   

human metabolite blood metabolite Chemicals and Drugs


代谢物信息卡片


5-{[(E)-{pyridin-3-yl[3-(trifluoromethyl)phenyl]methylidene}amino]oxy}pentanoic acid

化学式: C18H17F3N2O3 (366.1191208)
中文名称: 利多格雷
谱图信息: 最多检出来源 Homo sapiens(blood) 27.78%

分子结构信息

SMILES: C1=CC(=CC(=C1)C(F)(F)F)C(=NOCCCCC(=O)O)C2=CN=CC=C2
InChI: InChI=1S/C18H17F3N2O3/c19-18(20,21)15-7-3-5-13(11-15)17(14-6-4-9-22-12-14)23-26-10-2-1-8-16(24)25/h3-7,9,11-12H,1-2,8,10H2,(H,24,25)/b23-17+

描述信息

Ridogrel is only found in individuals that have used or taken this drug. It is a dual action drug useful for the prevention of systemic thrombo-embolism and as an adjunctive agent to thrombolytic therapy in acute myocardial infarction. However, there currently are no clinical indications for preferential use of ridogrel over aspirin.Ridogrel inhibits thromboxane A2 synthase and also blocks the thromboxane A2/prostaglandin endoperoxide receptors. Thromboxane synthetase produces thromboxane in platelets. Thromboxane is a vasoconstrictor and facilitates the clumping of platelets. Therefore by inhibiting the production and promotion of thromboxane, thrombolysis is enhanced.
C78275 - Agent Affecting Blood or Body Fluid > C1327 - Antiplatelet Agent
D006401 - Hematologic Agents > D010975 - Platelet Aggregation Inhibitors
D005765 - Gastrointestinal Agents
D004791 - Enzyme Inhibitors
C471 - Enzyme Inhibitor

同义名列表

3 个代谢物同义名

5-{[(E)-{pyridin-3-yl[3-(trifluoromethyl)phenyl]methylidene}amino]oxy}pentanoic acid; 5-((((3-Pyridinyl)(3-(trifluoromethyl)phenyl)methylene)amino)oxy)pentanoic acid; Ridogrel



数据库引用编号

7 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

1 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • Krishnaprasad Baby, Swastika Maity, Chetan H Mehta, Akhil Suresh, Usha Y Nayak, Yogendra Nayak. Targeting SARS-CoV-2 RNA-dependent RNA polymerase: An in silico drug repurposing for COVID-19. F1000Research. 2020; 9(?):1166. doi: 10.12688/f1000research.26359.1. [PMID: 33204411]
  • Fabiano E Xavier, Ana Paula C Davel, Lívia E Fukuda, Luciana V Rossoni. Chronic ouabain treatment exacerbates blood pressure elevation in spontaneously hypertensive rats: the role of vascular mechanisms. Journal of hypertension. 2009 Jun; 27(6):1233-42. doi: 10.1097/hjh.0b013e32832a391f. [PMID: 19337130]
  • M I Rosón, E Speziale, M M Celentano, G W Vega, P F Damiano, A M Puyó, I J de la Riva. Serotonin hypersensitivity in aorta of two kidney-two clip hypertensive rats: calcium contribution and prostanoids-nitric oxide interactions. Archives of physiology and biochemistry. 2001 Feb; 109(1):32-7. doi: 10.1076/apab.109.1.32.4288. [PMID: 11471069]
  • P Cirillo, P Golino, M Ragni, C Battaglia, F Pacifico, S Formisano, C Buono, M Condorelli, M Chiariello. Activated platelets and leucocytes cooperatively stimulate smooth muscle cell proliferation and proto-oncogene expression via release of soluble growth factors. Cardiovascular research. 1999 Jul; 43(1):210-8. doi: 10.1016/s0008-6363(99)00006-1. [PMID: 10536706]
  • R Soyka, B D Guth, H M Weisenberger, P Luger, T H Müller. Guanidine derivatives as combined thromboxane A2 receptor antagonists and synthase inhibitors. Journal of medicinal chemistry. 1999 Apr; 42(7):1235-49. doi: 10.1021/jm9707941. [PMID: 10197967]
  • D W Quest, T W Wilson. Effects of ridogrel, a thromboxane synthase inhibitor and receptor antagonist, on blood pressure in the spontaneously hypertensive rat. Japanese journal of pharmacology. 1998 Dec; 78(4):479-86. doi: 10.1254/jjp.78.479. [PMID: 9920205]
  • N H Naran, N Chetty. The in vitro effect of ridogrel on platelet function in normocholesterolaemic and familial hypercholesterolaemic type IIa subjects. Thrombosis research. 1997 Dec; 88(5):399-407. doi: 10.1016/s0049-3848(97)00271-5. [PMID: 9556227]
  • M H Carvalho, Z B Fortes, D Nigro, M A Oliveira, R Scivoletto. The role of thromboxane A2 in the altered microvascular reactivity in two-kidney, one-clip hypertension. Endothelium : journal of endothelial cell research. 1997; 5(3):167-78. doi: 10.3109/10623329709053396. [PMID: 9272380]
  • G Heinisch, W Holzer, F Kunz, T Langer, P Lukavsky, C Pechlaner, H Weissenberger. On the bioisosteric potential of diazines: diazine analogues of the combined thromboxane A2 receptor antagonist and synthetase inhibitor Ridogrel. Journal of medicinal chemistry. 1996 Sep; 39(20):4058-64. doi: 10.1021/jm960341g. [PMID: 8831771]
  • G W Vega, M I Rosón, A Bellver, M M Celentano, I J de la Riva. Nitric oxide and superoxide anions in vascular reactivity of renovascular hypertensive rats. Clinical and experimental hypertension (New York, N.Y. : 1993). 1995 Jul; 17(5):817-35. doi: 10.3109/10641969509033637. [PMID: 7655450]
  • P Cozzi, A Giordani, M Menichincheri, A Pillan, V Pinciroli, A Rossi, R Tonani, D Volpi, M Tamburin, R Ferrario. Agents combining thromboxane receptor antagonism with thromboxane synthase inhibition: [[[2-(1H-imidazol-1-yl)ethylidene]amino]oxy]alkanoic acids. Journal of medicinal chemistry. 1994 Oct; 37(21):3588-604. doi: 10.1021/jm00047a016. [PMID: 7932586]
  • J C Keith, Y Endo, K Warwick, K E Keith, S Brugh, T K Rowles. Ridogrel improves maternal/fetal homeostasis in an ovine model of pregnancy-induced hypertension. Prostaglandins. 1994 Mar; 47(3):247-63. doi: 10.1016/0090-6980(94)90064-7. [PMID: 8016393]
  • R Soyka, A Heckel, J Nickl, W Eisert, T H Müller, H Weisenberger. 6,6-Disubstituted Hex-5-enoic acid derivatives as combined thromboxane A2 receptor antagonists and synthetase inhibitors. Journal of medicinal chemistry. 1994 Jan; 37(1):26-39. doi: 10.1021/jm00027a004. [PMID: 8289199]
  • J M Ritter, S E Barrow, H S Doktor, P D Stratton, J S Edwards, J A Henry, S Gould. Thromboxane A2 receptor antagonism and synthase inhibition in essential hypertension. Hypertension (Dallas, Tex. : 1979). 1993 Aug; 22(2):197-203. doi: 10.1161/01.hyp.22.2.197. [PMID: 8340155]
  • J C Keith, J A Goodrich, Y Endo, D Taub, P Mehlman, G Ward. Effects of ridogrel on the prostacyclin-thromboxane ratio in nulliparous third trimester-pregnant rhesus monkeys. Prostaglandins. 1993 Jun; 45(6):547-55. doi: 10.1016/0090-6980(93)90018-3. [PMID: 8337414]
  • J De Cree, H Geukens, P Gutwirth, F De Clerck, E Vercammen, H Verhaegen. The effect of a combined administration of ridogrel and ketanserin in patients with intermittent claudication. International angiology : a journal of the International Union of Angiology. 1993 Mar; 12(1):59-68. doi: . [PMID: 8376914]
  • P Golino, G Ambrosio, B Villari, M Ragni, A Focaccio, L Pace, F de Clerk, M Condorelli, M Chiariello. Endogenous prostaglandin endoperoxides may alter infarct size in the presence of thromboxane synthase inhibition: studies in a rabbit model of coronary artery occlusion-reperfusion. Journal of the American College of Cardiology. 1993 Feb; 21(2):493-501. doi: 10.1016/0735-1097(93)90694-v. [PMID: 8426016]
  • C Weber, J R Beetens, F Tegtmeier, P Van Rooy, E Vercammen, L Wouters, F De Clerck. Ridogrel inhibits systemic and renal formation of thromboxane A2 and antagonizes platelet thromboxane A2/prostaglandin endoperoxide receptors upon chronic administration to man. Thrombosis and haemostasis. 1992 Aug; 68(2):214-20. doi: 10.1055/s-0038-1656351. [PMID: 1412169]
  • P Golino, G Ambrosio, I Pascucci, M Ragni, E Russolillo, M Chiariello. Experimental carotid stenosis and endothelial injury in the rabbit: an in vivo model to study intravascular platelet aggregation. Thrombosis and haemostasis. 1992 Mar; 67(3):302-5. doi: 10.1055/s-0038-1648436. [PMID: 1641819]
  • M F Bureau, F De Clerck, J Lefort, C D Arreto, B B Vargaftig. Thromboxane A2 accounts for bronchoconstriction but not for platelet sequestration and microvascular albumin exchanges induced by fMLP in the guinea pig lung. The Journal of pharmacology and experimental therapeutics. 1992 Feb; 260(2):832-40. doi: NULL. [PMID: 1738127]
  • T Di Perri, M Notari, G Assogna. [Ridogrel, a new platelet antiaggregant molecule with a double mechanism of action. A pharmacological and clinical profile]. Recenti progressi in medicina. 1991 Oct; 82(10):533-40. doi: NULL. [PMID: 1759039]
  • C Timmermans, M Vrolix, J Vanhaecke, F Stammen, J Piessens, E Vercammen, H De Geest. Ridogrel in the setting of percutaneous transluminal coronary angioplasty. The American journal of cardiology. 1991 Aug; 68(5):463-6. doi: 10.1016/0002-9149(91)90779-k. [PMID: 1872272]
  • S S Bhagwat, C Gude, D S Cohen, W Lee, P Furness, F H Clarke. Thromboxane receptor antagonism combined with thromboxane synthase inhibition. 1. (+/-)-(3-pyridinylbicycloheptyl)alkanoic acids. Journal of medicinal chemistry. 1991 Jun; 34(6):1790-7. doi: 10.1021/jm00110a006. [PMID: 1829485]
  • C Weber, J R Beetens, R Van de Wiele, M Höller, F De Clerck. Production of thromboxane and prostaglandins in human blood in the presence of thromboxane synthase inhibitors: a comparison of RIA and GC/MS determinations. Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis. 1991 Feb; 2(1):7-15. doi: 10.1097/00001721-199102000-00002. [PMID: 1773000]
  • I S Watts, K A Wharton, B P White, P Lumley. Thromboxane (Tx) A2 receptor blockade and TxA2 synthase inhibition alone and in combination: comparison of anti-aggregatory efficacy in human platelets. British journal of pharmacology. 1991 Feb; 102(2):497-505. doi: 10.1111/j.1476-5381.1991.tb12200.x. [PMID: 1826620]
  • N A Abbas, C Taube, R Hirschelmann, H J Mest. Thromboxane plasma level in kappa-carrageenin-induced acronecrosis of the tail in rats. Biomedica biochimica acta. 1991; 50(7):937-41. doi: NULL. [PMID: 1759973]
  • R H Bourgain, R Andries, K Decuyper, F De Clerck. Dual inhibition of thromboxane A2 synthesis and thromboxane A2/prostaglandin endoperoxide receptors by ridogrel: anti-thrombotic effect in vivo in rat mesenteric arteries. Journal of lipid mediators. 1991 Jan; 3(1):3-11. doi: ". [PMID: 1837488]
  • A Banic, K Kouris, N Rajacic, M Nazzal, N M al-Ghussain, O Thulesius. Effect of Ridogrel, a thromboxane receptor blocker and synthesis inhibitor on plasma and red blood cell flow in an arterial skin flap in sheep. Scandinavian journal of plastic and reconstructive surgery and hand surgery. 1991; 25(1):9-14. doi: 10.3109/02844319109034916. [PMID: 1828908]
  • S K Yao, M Rosolowsky, H V Anderson, P Golino, J M NcNatt, F De Clerck, L M Buja, J T Willerson. Combined thromboxane A2 synthetase inhibition and receptor blockade are effective in preventing spontaneous and epinephrine-induced canine coronary cyclic flow variations. Journal of the American College of Cardiology. 1990 Sep; 16(3):705-13. doi: 10.1016/0735-1097(90)90363-t. [PMID: 2143767]
  • B Hoet, J Arnout, C Van Geet, H Deckmyn, R Verhaeghe, J Vermylen. Ridogrel, a combined thromboxane synthase inhibitor and receptor blocker, decreases elevated plasma beta-thromboglobulin levels in patients with documented peripheral arterial disease. Thrombosis and haemostasis. 1990 Aug; 64(1):87-90. doi: . [PMID: 2148849]
  • F De Clerck, W Loots, Y Somers, J Beetens, L Wouters, J Wynants, P A Janssen. 5-Hydroxytryptamine and arachidonic acid metabolites modulate extensive platelet activation induced by collagen in cats in vivo. British journal of pharmacology. 1990 Apr; 99(4):631-6. doi: 10.1111/j.1476-5381.1990.tb12982.x. [PMID: 2113823]
  • B Hoet, C Falcon, S De Reys, J Arnout, H Deckmyn, J Vermylen. R68070, a combined thromboxane/endoperoxide receptor antagonist and thromboxane synthase inhibitor, inhibits human platelet activation in vitro and in vivo: a comparison with aspirin. Blood. 1990 Feb; 75(3):646-53. doi: NULL. [PMID: 2153424]
  • F De Clerck, J Beetens, D de Chaffoy de Courcelles, E Freyne, P A Janssen. R 68 070: thromboxane A2 synthetase inhibition and thromboxane A2/prostaglandin endoperoxide receptor blockade combined in one molecule--I. Biochemical profile in vitro. Thrombosis and haemostasis. 1989 Feb; 61(1):35-42. doi: NULL. [PMID: 2546278]
  • F De Clerck, J Beetens, A Van de Water, E Vercammen, P A Janssen. R 68 070: thromboxane A2 synthetase inhibition and thromboxane A2/prostaglandin endoperoxide receptor blockade combined in one molecule--II. Pharmacological effects in vivo and ex vivo. Thrombosis and haemostasis. 1989 Feb; 61(1):43-9. doi: NULL. [PMID: 2526385]
  • N Aoki, G Johnson, M R Siegfried, A M Lefer. Protective effects of a combination thromboxane synthesis inhibitor-receptor antagonist, R-68070, during murine traumatic shock. Eicosanoids. 1989; 2(3):169-74. doi: . [PMID: 2534278]